Satisfaction and adherence with glatiramer acetate [amount hidden] TIW in RRMS after 12 months, and the effect of switching from [amount hidden] QD

What Was Tested

This randomized controlled trial paper looks at Glatiramer Acetate.

Patient satisfaction with treatment in relapsing-remitting multiple sclerosis (RRMS) has a direct impact on adherence to treatment and, consequently, upon treatment outcomes and costs.

Patient-reported outcomes (PROs) are a common method for determining patient satisfaction in MS and other diseases.

Who Took Part

The study group was 789 patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The 12-month, open-label, Phase IV CONFIDENCE study assessed patient satisfaction and treatment adherence, using PROs, as well as safety outcomes in patients with RRMS treated with glatiramer acetate (GA).

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Glatiramer Acetate and who got the comparison, which limits bias.

Being open-label, the Glatiramer Acetate study did not mask who received what.

What Was Measured

Patient satisfaction with treatment in relapsing-remitting multiple sclerosis (RRMS) has a direct impact on adherence to treatment and, consequently, upon treatment outcomes and costs.

Patient-reported outcomes (PROs) are a common method for determining patient satisfaction in MS and other diseases.

Topics PubMed links to this paper include Glatiramer Acetate, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting, Outcome Assessment, Health Care, Patient Satisfaction and Drug Monitoring.

The authors tagged it with the keywords Adherence, Copaxone and RRMS.

What This Means in Plain Language

The paper is a randomized and open-label study of Glatiramer Acetate in 789 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Multiple sclerosis and related disorders), a journal based in Netherlands.

More context: the Glatiramer Acetate compound page, all human trials.